Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

ff4EuroHPC second open call: urgent PS for manufacturer of devices such as inhalers, nebulizers, aerosols or small/medium pharma/biotech companies using this kind of devices for drug delivery

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDES20210908001
Publicado:
13/09/2021
Caducidad:
21/09/2021
Resumen:
A Spanish computational engineering company is looking for a manufacturer or final user of inhalers, aerosols, nebulizers to join a project that aims to develop a novel software tool to optimise intranasal drug delivery to be applied to the ff4EuroHPC second open call. The company should be able to test the technology and validate the product.

Details

Tittle:
ff4EuroHPC second open call: urgent PS for manufacturer of devices such as inhalers, nebulizers, aerosols or small/medium pharma/biotech companies using this kind of devices for drug delivery
Summary:
A Spanish computational engineering company is looking for a manufacturer or final user of inhalers, aerosols, nebulizers to join a project that aims to develop a novel software tool to optimise intranasal drug delivery to be applied to the ff4EuroHPC second open call. The company should be able to test the technology and validate the product.
Description:
Intranasal drug delivery is a well known technique for the treatment of respiratory diseases, with promising outcomes for nose-to-brain drug delivery and also usage for vaccines administration. The value of the worldwide nasal drug delivery market will reach -Y-euro;60.93bn by 2026, growing at a rate of 7.3% per year between 2018 and 2026.
Devices used for this purpose are far from being optimum, and the tools used to assess device´s efficiency are expensive in terms of time and cost. A Spanish computational engineering company has developed an automatised software tool based on CT imagery and Computational Fluids Dynamics (CFD) simulations of drug delivery in human nasal cavities able to study systematically the particle deposition of each patient depending on the device and fluid used (without invasive or time consuming procedures) thus saving time and money and optimising patients´ treatment.
Understanding nasal deposition patterns resulting from intranasal dosage forms is a key aspect in the development of effective nasally administered drug products The deposition efficiency of nasal devices depends on the airway geometry as well as the device properties. The company has developed computational models capable of predicting particle deposition patterns in different nasal cavities, aiding to improve nasal dosage forms and devices. CT scan of the patient is used to segment the nasal cavity region. Based on this output, a 3D virtual reconstruction of the upper airway is obtained. The set of fluid mechanics equations is solved using FVM following paradigm of parallel computing, in order to scale the computations to the number of cores available for a faster delivery of results to the client. Database of sprays and nebulizers assessed with different physical models (considering particle break-up, evaporation...) will be included within the service. Besides particle deposition patterns and efficiency, variables like pressure, temperature and velocity are also obtained.
In order to continue the development of the product and dramatically improve the performance (based on High Performance Computing) the company is planning to apply to ff4EuroHPC programme: https://www.ff4eurohpc.eu/en/
The company is looking for a partner able to test the technology and validate the product. The perfect candidate would be a manufacturer of devices such as inhalers, nebulizers, aerosols, etc. or small/medium pharma/biotech company using this kind of devices for drug delivery. As a preliminary approach, partner could provide features and CAD geometry of the new device (together with fluid properties) and assess the performance in several human nasal cavities, in order to optimise it for the most of the patients or to use it as a guideline for certain kind of patient or treatment (for example, perforated nasal septum, deviated septum, empty nose syndrome, or even general parameters like age, race, gender...after an in depth study). This can be further discussed.
The partner must be from one of the following countries: Austria, Belgium, Latvia, Bulgaria, Lithuania, Luxembourg, Cyprus, Malta, Czechia, Netherlands, Denmark, Ireland, Poland, Estonia, Portugal, Finland, Romania, Slovakia, Slovenia, Hungary or Sweden.

Official deadline for the call: 29th of September

Deadline for the EoI: 21st of September

Expected duration of experiments: maximum 15 months with expected commencement 1st March 2022

Funding for Call-2: The indicative total funding budget is -Y-euro; 5 M.

Maximum funding request per proposal: -Y-euro; 200,000 (covering all participants)




Advantages and Innovations:
The project is aiming at creating software products based on digital twins by means of a novel software tool that would optimise intranasal drug delivery. It will be based on 3D virtual replicas of the patients´ upper respiratory tract and numerical simulation of fluid flow and particle transport and will be able to computationally assess particle deposition patterns and personalised treatments and devices without invasive techniques or implications for the patient.

Partner sought

Partner Sought:
The company is looking for a small/medium company manufacturing medical devices such as inhalers, nebulizers or aerosols or a pharma/biotech company using this kind of devices for drug delivery that would be able to test a novel software tool that optimises intranasal drug delivery. As a preliminary approach, the partner could provide features and CAD geometry of the new device (together with fluid properties) and assess the performance in several human nasal cavities, in order to optimise it for the most of the patients or to use it as a guideline for certain kind of patient or treatment (for example, perforated nasal septum, deviated septum, empty nose syndrome, or even general parameters like age, race, gender...after an in depth study).
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No

Dissemination

Restrict dissemination to specific countries:
Austria
Belgium
Bulgaria
Cyprus
Czech_Republic
Denmark
Estonia
Finland
Hungary
Ireland
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Poland
Portugal
Romania
Slovakia
Slovenia
Sweden

Programme-call

Framwork Programme:
Digital Content
Coordinator Required:
No
Deadline for Call:
29/09/2021
Weblink to the Call: